Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03389750 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03389750 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 16 participants.
The verdict
NCT03389750, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Significant public health concerns have arisen from the intravenous misuse of oxymorphone, a potent mu-opioid pain medication. However, little is known about its abuse potential relative to other mu-opioid analgesics. The present study is designed to examine the abuse liability of intravenous oxymorphone compared to other mu opioid agonists (oxycodone, and hydromorphone) among physically dependent opioid abusers.
Interventions
- DRUG Intravenous Challenge Drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-03-15 |
| Est. Completion | 2023-06-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03389750
The ClinicalTrials.gov registry entry for NCT03389750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravenous Challenge Drug is the first listed.
NCT03389750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03389750 about?
NCT03389750 is a clinical study titled "A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.". Significant public health concerns have arisen from the intravenous misuse of oxymorphone, a potent mu-opioid pain medication. However, little is known about its abuse potential relative to other mu-opioid analgesics. The present study is designed to examine the abuse liability of intravenous oxymor...
What is the current status of trial NCT03389750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-03-15. Estimated completion is 2023-06-28.
What interventions are being tested in trial NCT03389750?
The interventions under investigation include: Intravenous Challenge Drug (DRUG).
Who is sponsoring clinical trial NCT03389750?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.